Alentis Therapeutics
Alentis Therapeutics targets Claudin-1, a protein exposed on squamous cancers and scarred organs, with antibodies that either carry a cancer-killing drug or block disease signalling. Its first cancer medicine entered human trials in 2025.
Overview
Alentis Therapeutics is a clinical-stage Basel biotech focused on Claudin-1 (CLDN1), a tight-junction protein that becomes exposed on tumour cells and in fibrotic tissue. Its oncology pipeline comprises ALE.P02, a CLDN1-directed antibody-drug conjugate with a tubulin inhibitor payload for advanced or metastatic CLDN1-positive squamous solid tumours (FDA IND clearance October 2024, Fast Track designation November 2024, phase 1/2 trial planned from Q1 2025), and ALE.P03, a CLDN1 ADC with a topoisomerase 1 inhibitor payload entering first-in-human studies in 2025. The monoclonal antibody lixudebart (ALE.F02) is in development for organ fibrosis, with topline results in ANCA-associated glomerulonephritis and advanced liver fibrosis reported in January 2025. In November 2024 Alentis raised an oversubscribed USD 181.4 million Series D led by OrbiMed with co-leads Novo Holdings and Jeito Capital. Mark Pruzanski was appointed CEO in October 2025.
Funding
All startups| Round | Year | Amount | Source |
|---|---|---|---|
| Series D | 2024 | $181M | alentis.ch |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Notes
top- Earlier rounds (Series A to C) not fetched and omitted.
Pages like this
not linked directly; found by shared links- CompanyAdcendo
Shares Bpifrance, Jeito Capital, Novo Holdings, OrbiMed.
- CompanyCallio Therapeutics
Shares Jeito Capital, Novo Holdings, Frazier Life Sciences, Antibody-drug conjugate (ADC).
- CompanyEnliven Therapeutics
- CompanyAdela
Shares OrbiMed, RA Capital Management.
- CompanyObsidian Therapeutics
Shares Novo Holdings, RA Capital Management.
- CompanyAlpha-9 Oncology
- CompanyEnlaza Therapeutics
Shares Frazier Life Sciences, Antibody-drug conjugate (ADC).
- CompanyBigHat Biosciences
Shares Monoclonal antibodies, Antibody-drug conjugate (ADC).